Welcome to the HCV Advocate’s DDW Conference coverage.  In an effort to best serve our readership, we will post all the important and interesting abstracts about HCV from the conference.  While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.  The other abstracts posted to the web site are HCV related abstracts posted to www.ddw.org that we have not been able to report on or update.  

To locate specific abstracts on this page, click on “Edit” at the top of  your browser (Microsoft Internet Explorer) and then on Find (on this page).  In Netscape, click on “Search” and then on “Find in This Page.” Simply type in a word or term and the search engine will list the related abstracts.

Please click here to view our fact sheet on reading and understanding an abstract.

Thank You,

Alan Franciscus


Hepatitis C


AcuteFactors that influence spontaneous viral clearance of hepatitis C.

Cirrhosis and End Stage Liver DiseaseComplications and management of conditions such as portal hypertension, ascites, liver cancer and encephalopathy.

CoinfectionDisease progression, epidemiology, and liver transplantation.

Current TreatmentFDA approved medications to treat hepatitis C, side effect management, disease progression after successful treatment, and treatment of various populations of people with hepatitis C.

Diagnostic ToolsVarious tests to diagnose and manage hepatitis C including various biochemical marker, imaging, liver biopsy for grading/staging liver disease and HCV RNA (viral load) tests.

Disease ProgressionVarious factors that influence HCV disease progression including steatosis, obesity, insulin resistance, diabetes, race/ethnicity, and general studies on disease progression.

Epidemiology, Natural History, DiagnosisStudies that look at populations infected with hepatitis C as well as the transmission risk factors.

Experimental TherapiesNew treatments for hepatitis C including pre-clinical development that have not yet been studied in humans, and various drugs that are in phase I, II and III development to treat hepatitis C.

TransplantationInformation on allocation of livers, recurrent HCV after transplantation, effect of race/ethnicity, immunosuppressant drugs, post transplant HCV disease progression, and pediatric issues.


Hepatitis B